AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

GABAPENTIN 300.000 Mg ;

9 registrations across 1 African market— 9 active

Markets with GABAPENTIN 300.000 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
Shalgaten 300 mg
Hard Gelatin Capsules
🇪🇬EgyptMash tech for pharmaceutical industries - local under constructionactive
Gabimash 300MG
Tablets
🇪🇬EgyptBio Med For Pharmaceutical Industries (BIOMED)active
GABAPENTIN 300mg
Hard Gelatin Capsules
🇪🇬Egyptuniversal pharmaceutical industries (unipharma)active
Shalgaten 300 mg
Hard Gelatin Capsules
🇪🇬EgyptMash tech for pharmaceutical industries - local under constructionactive
GABAPENTIN 300mg
Hard Gelatin Capsules
🇪🇬Egyptuniversal pharmaceutical industries (unipharma)active
NEURONTIN 300mg
Hard Gelatin Capsules
🇪🇬EgyptViatris Egyptactive
Gralipentin 300 mg
Extended Release Film Coated Tablets
🇪🇬EgyptATCO Pharma for Pharmaceutical Industriesactive
Gralipentin 300 mg
Extended Release Film Coated Tablets
🇪🇬EgyptATCO Pharma for Pharmaceutical Industriesactive
Gabimash 300MG
Tablets
🇪🇬EgyptBio Med For Pharmaceutical Industries (BIOMED)active

GABAPENTIN 300.000 Mg ; in Africa — Regulatory Overview

GABAPENTIN 300.000 Mg ; is registered across 1 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 9 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.